In addition, a recent analysis of global HypoCCS data revealed a standardized incidence ratio for all cancers of 0.88 (95% CI, 0.74–1.04) in GH-treated patients globally and, among US patients, the standardized incidence ratio was 0.94 (95% CI, 0.73–1.18) for GH-treated patients and 1.16 (95% CI, 0.76–1.69) for untreated patients (6). Here, GH1 is linked to cancer.